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Context. General rates of over- and under-replacement in levo-thyroxine (L-T4) users with 
primary hypothyroidism are variably high. No information on L-T-4 adequacy exists in 
obesity. 
Objective: We explored rates and factors relating to L-T4 adequacy in obese patients with 
primary hypothyroidism. 
Setting. Tertiary care center. 
Design. Among 4954 consecutive obese patients admitted between 2011-2014, 691 
hypothyroid patients on L-T4 therapy and 691 BMI-, age- and gender-matched euthyroid 
controls underwent analysis of thyroid function, gluco-lipid profile, body composition and 
indirect calorimetry. L-T4 users were classified into low TSH (<0.27 mU/liter), euthyroid 
(0.27-4.2 mU/liter) and high TSH (>4.2 mU/liter).  
Results. L-T4 users constituted 13.9% of the incident population. TSH was low in 7.5%, high 
in 17.2% and normal in 75.2% of L-T4 users. Over-treatment decreased with aging and more 
L-T4 users ≥65y had normal TSH than those <65y (p<0.05). Compared to the euthyroid 
obese group, L-T4 users showed higher adiposity, similar insulin resistance but an healthier 
lipid profile. In multivariable analyses, L-T4 dose was predicted by fat-free mass, 
hypothyroidism cause, and gender (p<0.0001 to <0.05). Risk of L-T4 over-replacement 
increased with younger age (OR 0.96; 95% CI 0.94-0.99), higher L-T4 dose (OR 2.98; 95% 
CI 1.44-6.14) and lower BMI (OR 0.93; 95% CI 0.88-0.99). Male gender increased the 
likelihood of L-T4 under-replacement (OR 2.37; 95% CI 1.10-5.11).  
Conclusions. Obesity is associated with milder rates of inadequate L-T4 treatment compared 
to non-obese populations. L-T4 adequacy increases with aging. Age, body composition and 
gender are main the determinants of L-T4 requirements in obesity. 
Rates of over- and under-treatment are milder in obese L-T4 users than reference non-obese 
populations and improve with aging. Age, body composition and gender influence L-T4 requirements 
in obesity. 
Introduction 
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Obesity and thyroid abnormalities are common conditions closely linked together from 
clinical and molecular viewpoints (1). This relationship has become clinically relevant in the 
context of an unprecedented rise in the prevalence of obesity worldwide (2). Because thyroid 
hormone plays important roles in energy homeostasis and gluco-lipid metabolism (1), thyroid 
dysfunctions are often associated with perceived or factual changes in body composition and 
resting energy expenditure (REE) independent of physical activity (3).  
Levo-thyroxine (L-T4) is the treatment of choice when the diagnosis of persistent thyroid 
hormone deficiency is confirmed (4-6). With the exception of central hypothyroidism or 
peripheral thyroid hormone resistance, individualized L-T4 dose up-titration is 
conventionally determined by circulating TSH, the established biomarker of L-T4 
replacement (7-11). Reaching a TSH value within the age-adjusted euthyroid range is the 
accepted therapeutic target (4,5,12-14), as it promotes improvements in symptoms, quality of 
life and cardiovascular risk (15-22). The therapeutic management of primary hypothyroidism 
with L-T4 is considered relatively uncomplicated, and aided by reliably accurate TSH and 
thyroid hormone immunoassays. Despite reaching TSH within the euthyroid range, however, 
some patients face modest improvements in bodyweight and lipid abnormalities during long-
term L-T4 replacement (5,23,24). Moreover, epidemiology studies found that as many as 
57% of patients undergoing L-T4 replacement can experience therapy over- or under-
replacement, even when frequent biochemical monitoring is accomplished (13,25-27). 
Aspects of previously unrecognized complexity in the therapeutic management of 
hypothyroidism have also been underscored in special populations, in particular older 
patients, children, pregnant women and obese individuals (4-6,13,14,28). Common reasons 
for incorrect L-T4 replacement include non-adherence, medication administration errors, 
dietary factors, medication interference, as well as impaired L-T4 absorption (4-6,14,29-31).  
To date, the rate of abnormal thyroid function testing and its metabolic associates in 
obese subjects undergoing L-T4 treatment for primary hypothyroidism remains unknown. 
Given the detrimental consequences of inadequate L-T4 replacement especially in the aging 
population, we conducted a cross-sectional investigation to define the prevalence and the 
factors associated with inadequate L-T4 replacement, and to evaluate the metabolic 
phenotype associated with L-T4 treated hypothyroidism in obese patients. 
Patients and Methods 
Of 4954 consecutive de novo patients admitted between 7th January 2011 and 28th December 
2014 to our Institution for work-up and rehabilitation of morbid obesity, 691 obese patients 
suffering from primary hypothyroidism on stable treatment with tablet L-T4 for at least 6 
months were included in the study [605 F/86 M; age, 59 yrs (IQR, 50-69 yrs); BMI, 43.9 
kg/m2 (IQR 40.1-48.4 kg/m2)]. All patients’ charts were individually reviewed where 
available to exclude inappropriate L-T4 prescriptions. The cause of primary hypothyroidism 
was autoimmune thyroid disease (AITD) in 609 patients (88.1%) and total thyroidectomy in 
82 cases (11.9%). None had suffered from thyroid cancer. A group of 691 BMI-, age- and 
gender-matched biochemically euthyroid obese patients referred to our unit for obesity in the 
same period, were enrolled according to the exclusion criteria and constituted the control 
group. Exclusion criteria were comorbidities affecting the evaluation of thyroid function, 
acute illness and/or acute inflammation, use of T3 or medications potentially interfering with 
thyroid function (such as amiodarone, steroids or lithium carbonate therapy) or L-T4 
absorption (such as cholestyramine, antacids, ferrous sulfate, sucralfate, laxatives, calcium 
carbonate, proton pump inhibitors, lovastatin, bile acid sequestrants) and  pregnancy. In all 
patients, body weight was stable for ≥6 months prior to study enrolment. The investigation 
was approved by the local Ethical Committee, functioning according to the 3rd edition of the 
Guidelines on the Practice of Ethical Committees in Medical Research On admission, and 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00773/5526754 by Biblioteca IR
C
C
S Fondazione Salvatore M
augeri, C
linica del Lavoro e della R
iabilitazione user on 09 July 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00773 
 
 
3
written consent was obtained from all patients. Main study outcomes included rates of over- 
and under-treatment in L-T4 users and factors associated with L-T4 adequacy. Secondary 
outcome measures included assessment of differences in metabolic profile between L-T4 
users and euthyroid controls. 
In all participants, body measurements were conducted on fasting patients wearing light 
underwear. Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, 
and BMI was expressed as body mass (kg)/height (m)2. The criterion of obesity was BMI ≥30 
kg/m2. Waist circumference (WC) was measured midway between the lowest rib and the top 
of the iliac crest after gentle aged expiration; hip was measured as the greatest circumference 
around the nates. Bio-impedance analysis (BIA, 101/S Akern; Florence, Italy) allowed 
measurement of percent fat mass (%FM) expressed and free fat mass (FFM, kg). 
Methodology, variation coefficients and exclusion criteria have been previously detailed (32). 
Resting energy expenditure (REE) was expressed in kilocalories per 24h and determined in a 
thermo-regulated room (22-24 °C) by computed open-circuit indirect calorimetry, measuring 
resting oxygen uptake and resting carbon dioxide production by a ventilated canopy 
(Sensormedics, Milan, Italy) at 1-min intervals for 30 min and expressed as 24 h value. 
Methodology, equation formulae and performance of different equations to predict measured 
REE have been previously described (33,34). 
Undiluted serum samples were assayed in duplicate for fT4 and TSH using an automated 
chemiluminescence assay system (Immulite 2000; DPC, Los Angeles, CA). The principle of 
the method is a two-site, solid-phase chemiluminescent immunometric assay or competitive 
immunoassay. L-T4 users were classified according to TSH levels, into one of the following 
three groups: patients with low serum TSH levels (TSH <0.27 mU/liter), euthyroid patients 
(TSH 0.27-4.20 mU/liter), and patients with high serum TSH (TSH >4.20 mU/liter). Within 
these groups, patients were then stratified according to their fT4 levels: high (fT4 >17.0 
ng/liter), normal (fT4 ≥9.0-17.0 ng/liter) and low fT4 (fT4 <9 ng/liter).  
Obese euthyroid controls underwent measurement of anti-thyroperoxidase (TPOAb) and 
anti-thyroglobulin (TgAb) antibodies by automated chemiluminescence assay system (Anti-
Tg, Anti-TPO Ready Pack, Siemens Healthcare Diagnostics, Milan). Thyroid ultrasound 
examination was performed in a subgroup of 47 controls having their TSH levels above the 
reference TSH range, to exclude antibody-negative AITD. Routine laboratory data included 
glucose, total cholesterol (CHO), high-density (HDL) and low-density lipoprotein (LDL) 
cholesterol and triglycerides (TG) measured by enzymatic methods (Roche Diagnostics, 
Mannheim, Germany). Ultrasensitive C-reactive protein (CRP) was measured by CRP (latex) 
HS Roche kit. Insulin levels were measured using a Cobas Integra 800 Autoanalyzer (Roche 
Diagnostics, Indianapolis, IN, USA), and insulin resistance was expressed as HOMA-IR 
[insulin (mIU/L) × [glucose (mmol/L)/22.5]]. Type 2 diabetes mellitus (T2DM) was 
ascertained by patients’ history and/or biochemistry analyses on admission according to 
current guidelines (35).  
Statistical analyses 
Statistical analyses were performed using SPSS version 21 (Somers, NY, USA) on log 
transformed data to correct for the non-Gaussian distribution obtained by the Shapiro-Wilk 
test. In the text and tables, values are expressed as median and interquartile ranges. 
Univariate ANOVA was used for comparison between groups. Spearman’s correlation 
analysis was used to identify significant associations between the variables of interest.  
Stepwise multivariable regression analysis was conducted to identify predictors of L-T4 
dose and the multilinear model included age, gender (female=0, male=1), BMI, FFM and 
%FM, REE, aetiology of hypothyroidism (AITD = 0, total thyroidectomy = 1), daily L-T4 
dose µg/kg of body weight (BW), duration of L-T4 treatment, and T2DM. β coefficients and 
significance values obtained from the models were reported. Multinomial logistic regression 
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analysis was performed to test the effect of variables of interest on the risk of under- and 
over-treatment with L-T4 therapy. Statistical significance was set at 5%. 
Results 
Obese L-T4 users  
L-T4 users accounted for 13.9% of all patients referred to our unit in the study period for 
morbid obesity. Most patients of the study population were severely obese: BMI was >40 
kg/m2 in 75.8%, >35.0-39.9 kg/m2 in 18.4%, and >30.0-34.9 kg/m2 in 5.8% of L-T4 users. 
Females accounted for 87.6%. Previously diagnosed or de novo T2DM affected 47.7% of 
cases. Anthropometric and metabolic profiles are summarized in Table 1. 
In the population as a whole, the median daily dose of L-T4 was 100 µg (IQR, 75-125), 
equivalent to 0.91 µg/kg/day (IQR, 0.61-1.17) when expressed relative to BW. As expected, 
the daily L-T4 µg/kg dose was lower in AITD than athyreotic patients [0.85 (IQR, 0.55-1.10) 
vs. 1.20 µg/kg/day (IQR, 0.91-1.40), p<0.01]. The difference in L-T4 µg/kg dose between 
females and males was not significant [(0.84 (IQR, 0.45-1.16) vs. 0.91 µg/kg/day (IQR, 0.61-
1.17), respectively]. 
The overall rate of patients with abnormal TSH was 24.7%. Individually, TSH levels 
were low in 7.5% (52 cases: TSH <0.27-0.1 mU/liter in 27 and <0.1 mU/liter in 25), high in 
17.2% (119 cases; TSH >4.20-10 mU/liter in 101 and >10 mU/liter in 18) and normal in the 
remaining 75.3% of cases. Moreover, high fT4 levels were observed in 13.4% of patients 
with low TSH, while 12.6% of those with high TSH had low fT4 levels. According to serum 
TSH, the rate of under-treated patients was higher than that of over-treated ones (χ2=17.80, 
p<0.0001). Compared to L-T4 users whose TSH was in the euthyroid range (Table 2), over-
replaced patients were younger, less obese, and took a higher daily dose of L-T4 µg/kg, while 
under-replaced patients were younger, predominantly males, showed higher abdominal 
obesity, FFM, insulin and insulin resistance, and took a lower daily dose of L-T4 µg/kg. A 
declining trend in FFM-adjusted REE was observed with decreasing L-T4 replacement. In 
analysis restricted to diabetic L-T4 users on chronic metformin treatment, this subgroup 
exhibited non-significantly lower TSH levels compared to non-diabetic L-T4 users [TSH, 
1.83 (IQR, 0.34-3.46) vs. 2.6 (IQR, 0.01-3.25) mU/liter; p=0.7], while proportions of over-
treated (5.2% vs. 7.3%) and under-treated (15.7% vs. 13.0%) patients were comparable 
between subgroups. 
TSH levels did not appear to change with increasing age (Figure 1). In the 238 L-T4 users 
aged 65y or older, however, the frequency of euthyroid TSH was marginally higher than in 
the younger counterpart (84% vs. 70.6%, p<0.05), owing to a progressive reduction in over-
treatment rates across increasing age decades (Figure 2). Cumulatively, low TSH levels 
suggestive of over-treatment were observed in <5% of patients aged >65 yr, while the rate of 
those with high TSH remained relatively constant across age decades. Gender distribution 
was similar between elderly and non-elderly subgroups. The anthropometric and metabolic 
study showed that elderly L-T4 users had a lower body weight, were more sarcopenic and, 
expectedly, took a lower L-T4 dose than their younger counterpart (Table 3).  
Correlation and regression analyses in obese L-T4 users 
Bivariate correlation analysis showed that the daily L-T4 dose was associated with many 
bodily variables, although FFM was the strongest correlate (Table 4). In a model including 
age, gender, cause of hypothyroidism, diabetes mellitus, %FM and FFM, as well as duration 
of L-T4 treatment, a stepwise multivariable regression analysis documented that daily L-T4 
µg/kg dose was best predicted by FFM (β=0.262, p<0.0001), total thyroidectomy (β=0.225, 
p<0.0001), and gender (β=-0.122, p<0.05). In multinomial logistic regression analysis, the 
likelihood of L-T4 over-replacement was associated with younger age, higher daily L-T4 
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µg/kg dose and lower BMI (Table 5). In contrast, the risk of under-replacement was only 
associated with male gender (p<0.05). 
Comparison with an euthyroid obese population 
To test for potential anthropometric and metabolic effects relating to L-T4 treatment in the 
obese setting, a comparably obese group of age-, sex- and BMI-matched euthyroid subjects 
was enrolled among inpatients regularly admitted to our unit for obesity workup during the 
study period. In this group, BMI was >40 kg/m2 in 77.6%, >35.0-39.9 kg/m2 in 16%, and 
>30.0-34.9 kg/m2 in 6.4% of cases. None suffered from inflammatory conditions and CRP 
levels were similar between populations. Despite having comparable BMIs, groups differed 
in terms of %FM and, non-significantly, FFM. Nevertheless, FFM-adjusted REE was higher 
in L-T4 users than euthyroid controls. There was no between-group difference in glucose and 
insulin levels, hence insulin resistance. Oppositely, L-T4 users exhibited a healthier lipid 
profile owing to lower total and LDL-cholesterol levels than euthyroid controls. These 
differences remained unchanged after excluding the subgroup of over- and under-replaced 
patients from the L-T4 group.  
Discussion 
L-T4 represents the first-line replacement treatment in primary hypothyroid patients with the 
aim to restore normal TSH secretion, promote patients’ well-being and reduce the systemic 
consequences of hypothyroidism (14). Studies in the general population reported a variably 
high proportion of patients with abnormal TSH during replacement therapy with L-T4, even 
in the case of frequent monitoring for dosing adjustments. In the Colorado Thyroid Study, 
abnormal TSH levels were documented in 40% of 1525 patients taking thyroid medications, 
with over a fifth of cases showing low TSH values (25). A UK survey on 1037 patients noted 
abnormal thyroid function testing in 37.2% of cases, with 17.4% being over-treated and 
19.8% being under-treated (26). Further, in 29.5% of 266 L-T4 users from the Pomerania 
study TSH levels were outside the reference range, and again more patients were over-
replaced than under-replaced, namely 19.5% vs. 10% of cases (27). Our analysis on obese 
individuals with primary hypothyroidism evaluated the prevalence of adequate L-T4 
treatment and attempted to gain insights on factors relating to abnormal thyroid testing in this 
cohort. Results highlight a peculiar role for obesity on L-T4 requirements, with nearly 75% of 
participants showing TSH levels within the euthyroid range. Among those with abnormal 
TSH, the rate of L-T4 under-replacement predominated as compared to that of over-
replacement, namely 17.2% vs. 7.5% of cases. The reason for this outcome remains unclear. 
Current general recommendations toward specialised management of obesity increase the 
chance of stricter follow-ups (36), thus that our finding could simply be the result of 
improved obesity management. Alternatively, several studies have shown that body weight is 
maintained at a stable range, known as the set-point, despite the variability in energy intake 
and expenditure (37). This regulatory physiology is largely governed by leptin, a known 
hypothalamic modulator of TRH secretion, which could act to cushion TSH variations in 
obese patients until a new metabolic set-point develops, such as that generated by weight loss 
obtained during an inpatient regime (33) or after bariatric surgery (38). Because of the cross-
sectionality of this study, the aptness of our interpretation remains to be verified in 
prospective studies achieving adequate variations in metabolic set-point. 
TSH was unrelated to age but aging was associated with an improving rate of euthyroid 
TSH levels. We observed that median dose of L-T4 µg/kg BW declined with age, a finding 
that corroborates previous studies and, in this cohort, is potentially linked to underlying 
sarcopenic obesity. In older people, inflammatory conditions or non-thyroidal illness could 
per se alter TSH and fT4 adequacy to assess genuine euthyroidism, while fT3 measurement 
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can improve results accuracy (39). As we did not measure fT3 levels, the potential influence 
of extra-thyroidal conditions on our results cannot be discriminated. However, acute illness 
and/or inflammation was verified upon clinical assessment and by measurement of CRP 
levels at study entry to avoid including potential cases. Of note, the prevalence of over-
treatment, a matter of concern for cardiac and skeletal health in the elderly, decreased with 
age and totalled 5% in patients aged 65y and over. This figure differs from data reported in 
the Cardiovascular Heart Study (13) and the Framingham Heart Study (40), where 
overtreatment rates in the elderly were 41% and 43%, respectively, while it overlaps with that 
obtained in an endocrine clinic population (41). The discrepancy could be explained by the 
circumstance that our referral center may admit patients undergoing endocrine surveillance 
elsewhere. Thus, we cannot dismiss the possibility of over-appraisal of L-T4 treatment 
adequacy in this subgroup. While endorsing current recommendations on adequate thyroid 
function monitoring in older L-T4 users (12,14), the apparent favourable outcome observed 
in our elderly cohort should be interpreted with caution, based on the evidence that target 
TSH levels during L-T4 treatment should be age-adjusted to avoid the risk of overtreatment 
in the elderly (12,14).  
In terms of L-T4 requirement, the median L-T4 dose was 0.91 µg/kg/day. Body weight is 
a good indicator for calculating an appropriate starting dose of L-T4, with other determinants 
including age, gender, body composition, cause and validation of hypothyroidism, as well as 
comorbidities, drugs, and adherence to therapy (4-11,14,42,43). Notwithstanding the 
suggestion that severe obesity may require higher than normal L-T4 doses due to impaired L-
T4 pharmacokinetics and T4 to T3 conversion (31), we failed to observe apparent defects in 
L-T4 absorption in this large obese group and confirmed earlier evidence showing that the 
weight-adjusted L-T4 dose decreases with increasing BMI (44,45). Moreover, our findings on 
fat-free mass confirm that lean mass exerts a predictive role on L-T4 dose (38,44), which has 
been linked to cellular processes of deiodination and thyroid hormone metabolism taking 
place in muscle cells (46).  
In the search for factors potentially associated with abnormal thyroid function testing, the 
role of anthropometric and metabolic variables of L-T4 users was explored according to 
patients’ TSH. Patients with low TSH were younger, took a higher L-T4 dose and exhibited a 
poorer lean mass relatively to body mass when compared to those with euthyroid TSH 
values. On the other hand, patients with high TSH levels also were younger and were more 
frequently males, more abdominally obese, and their L-T4 dose appeared disproportionately 
low relative to their lean mass. Resting energy expenditure normalized by fat-free mass 
appeared to decline across categories of L-T4 users with low to high TSH. This result 
substantiate the notion that thyroid hormone and thyrotoxicosis exerts stimulatory effects on 
protein metabolism, heat production and metabolic efficiency (1). Likewise, a recent 6-month 
interventional study by Samuels and coworkers (47), while failing to document a direct effect 
of L-T4 dose modifications on resting energy expenditure normalized for lean body mass, 
noticed that its increases correlated directly with increases in fT4 and fT3 levels and inversely 
with increases in TSH levels across the achieved range of TSH levels. At odds with findings 
obtained in the general population on the favourable effect of L-T4 replacement on the lipid 
profile (18-22), we could document only modest decrements of total and LDL-cholesterol 
along with declining levels of serum TSH in L-T4 users. In terms of glucose homeostasis, the 
high TSH subgroup harboured significantly higher insulin resistance and non-significantly 
higher glucose levels compared to the other subgroups. Previous studies informed on 
associations between insulin resistance and thyroid function summarized as follows: 1) a 
cross-sectional association exists between insulin resistance and TSH levels (48); 2) the 
hypothyroid state is linked to a cellular condition of insulin resistance in adipocytes and 
muscle cells (49,50); 3) treatment of hypothyroidism improves insulin resistance (51). While 
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these and our findings pinpoint the potential link between L-T4 adequacy and insulin 
resistance, we found that neither diabetes mellitus nor metformin treatment altered the risk of 
thyroid testing abnormalities. This lack of result adds argument to the ongoing debate on the 
relationship between diabetes mellitus and the risk of L-T4 over-treatment in the general 
population, where both positive (13) and negative (26) associations have been identified. 
With reference to the risk of abnormal thyroid testing, logistic regression analysis showed 
that the likelihood of overtreatment was associated with younger age, higher L-T4 dose and 
lower BMI, while only male gender increased the risk of L-T4 under-treatment. These results 
corroborate those of studies in non-obese populations, reporting a relationship between L-T4 
dose and overtreatment risk on one side, and between male gender and under-treatment risk 
on the other (13,52). Together, our results suggest that the adequacy of treatment in obesity is 
potentially associated with anthropometric and metabolic outcomes, and underscore the role 
of lean mass and age in regulating L-T4 requirements. Whether this implies that assessment 
of body composition in this setting may help titrating individual L-T requirements remains to 
be demonstrated.  
To implement our understanding of residual metabolic risks in obese subjects on L-T4, 
their metabolic profile was examined in comparison to an equally obese group of euthyroid 
controls. Despite the similarities in BMI distribution, adiposity was higher in L-T4 users than 
in euthyroid obese controls, which agrees with previous evidence that hypothyroid patients 
only experience modest reductions in fat mass (1). Moreover, about 15% of L-T4 treated 
subjects do not reach clinical euthyroidism (14) as a result of impaired intracellular T3 
production determined by the down-regulation of the deiodinase pathway (53). 
Hypothetically, the existence of underlying peripheral hypothyroidism may ultimately 
influence long term regulation of body composition and contribute to explain current 
observations. Nonetheless, the levels of total cholesterol and LDL-cholesterol were 
significantly lower in L-T4 treated than in euthyroid controls, without differences in HDL-
cholesterol and triglyceride levels. These findings fall in line with those of previous 
randomized crossover (19,23), double-blind placebo-controlled (20,21) and longitudinal 
studies (22) investigating on L-T4 effects on lipids in non-obese populations (19-23). Current 
results also agree with those of a meta-analysis showing a decreasing effect of L-T4 
replacement on total and LDL-cholesterol in L-T4 users, while HDL-cholesterol and 
triglyceride levels remained unaltered (54). Oppositely, a meta-analysis of 99 studies 
documented persistently higher total and LDL cholesterol levels were observed in L-T4 users 
compared to controls (24). Because of the lack of studies on lipids in L-T4 treated obese 
populations (55), we cannot draw conclusive clinical implications from our results.  
Our study depicts a real-world snapshot of L-T4 therapy in hypothyroid obesity. As such, 
it conveys a number of limitations, such as the cross-sectional design, the lack of fT3 
measurement and information on therapeutic adherence (56-59). As individual adequacy of 
L-T4 therapy was based on the incidental finding of normal TSH, this measure may 
inadequately reflect the long-term thyroid hormone replenishment status of these patients. 
Furthermore, this study did not include a group of lean hypothyroid L-T4 users to compare 
rates of inadequate L-T4 replacement in the general population. Rather, our study aim was to 
discriminate the effect of L-T4 on the metabolic phenotype of obesity. The strength of the 
clinical information originating from our investigation includes a lower than expected rate of 
inadequate L-T4 replacement, an improving L-T4 adequacy with aging, and a relationship 
between L-T4 requirement and gender, age and lean body mass in this obese cohort. While 
our results imply that a limited proportion of L-T4 users is over-treated among obese patients 
referring to an obesity clinic, current data also support the recommendation that TSH target 
during L-T4 replacement should be age-adjusted, and L-T4 adequacy should be especially 
monitored in elderly obese individuals to avoid the detrimental effect of over-treatment. 
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Figure 1: Correlation between serum TSH levels and age in obese L-T4 users. 
Figure 2: Prevalence of obese L-T4 users with low TSH (over-treated), euthyroid 
(adequately-treated) and high TSH (under-treated) subdivided according to the age decades. 
For each decade, proportions are expressed as percent values and the number of subjects is 
displayed in parentheses on the horizontal axis. 
Table 1. Summary of anthropometric and biochemical data obtained in obese L-T4 users 
and obese euthyroid controls (Eu-Thyr group). Data are expressed as median, with 
interquartile range in parentheses, or percentage. Comparison between populations was 
performed by ANOVA and χ2 test. 
Variables L-T4 group (n = 691) Eu-Thyr group (n = 691) p 
Males/females (N, %) 86/605 (12.4/87.6) 86/605 (12.4/87.6) 1 
Age (years) 59 (50-69) 58.0 (50.9-66) 0.9 
BMI (kg/m2) 43.9 (40.1-48.4) 44.3 (39.8-48.2) 0.5 
BMI >40 kg/m2 75.8% 77.6% 0.2 
Waist (cm) 123 (114-132) 122 (111-131) 0.6 
FM (%) 50.9 (46.6-54.2) 48.9 (44.4-53.0) <0.0001 
FFM (kg) 54.0 (48.3-59.8) 54.4 (49.1-61.6) 0.2 
REE (kcal/day) 1731 (1557-1940) 1711 (1491-1949) 0.2 
REEFFM 31.5 (2.6-34.4) 30.7 (27.1-33.8) <0.001 
TSH (mU/liter) 2.08 (0.96-3.69) 1.78 (1.20-2.70) <0.0001 
fT4 (ng/liter) 12.1 (10.8-13.6) 11.2 (10.2-12.5) <0.0001 
Glucose (mg/dL) 97.0 (88.0-114.8) 97.0 (86.0-111.0) 0.1 
Insulin (mU/liter) 13.1 (8.9-18.4) 13.4 (9.6-18.9) 0.2 
HOMA-IR 3.2 (2.1-4.8) 3.3 (2.2-5.2) 0.1 
CHO (mg/dL) 191 (166-219) 208 (182-233) <0.0001 
LDL-CHO (mg/dL) 120 (97-144) 129 (106-153.9) <0.0001 
HDL-CHO (mg/dL) 47 (39-56) 47 (39-54) 0.7 
TG (mg/dL) 130 (100-175) 130 (103-169) 0.5 
CRP (mg/dL) 0.7 (0.4-1.2) 0.7 (0.4-1.2) 0.7 
For abbreviations: BMI, body mass index; WHR, Waist-to-hip ratio, FM, fat mass; FFM, fat-free mass; REE, 
resting energy expenditure; TSH, thyroid-stimulating hormone; fT4, free thyroxine; HOMA-IR, homeostatic 
model of insulin resistance; CHO, total cholesterol; LDL, low density lipoprotein; HDL, high density 
lipoprotein; TG, triglycerides; CRP, C-reactive protein. 
Table 2. Summary of data obtained in obese L-T4 users, subdivided as adequately, under-
treated and over-treated patients. Data are expressed as median, with interquartile range in 
parentheses. Comparison between populations was performed by ANOVA test and χ2 test. 
Significant differences between adequately treated and under-treated or over-treated group 
are expressed as: *, p<0.05; *1, p<0.01; *2, p<0.001; *3, p<0.0001. Significant differences 
between under-treated and over-treated group are expressed as: §, p<0.05; §, 1p<0.01; §2, 
p<0.001; §3, p<0.0001. 
Variables Adequately treated (n = 519) Under-treated (n = 119) Over-treated (n = 52) 
Males/females (N, %) 50/469 (9.6/90.4) 30/89 (25.2/74.8)*3 6/46 (11.5./98.5)§ 
Age (years) 60 (51-70) 57 (49-64)* 54 (48-63)*2 
BMI (kg/m2) 44.1 (40.2-48.5) 44.5 (41.0-49.6) 40.6 (37.1-43.7)*2, §3 
Waist (cm) 123 (113-132) 127 (116-139)* 120 (110-125)*, §2 
FM (%) 51.0 (47.2-54.5) 49.5 (43.6-53.9) 50.0 (44.7-53.0) 
FFM (kg) 53.7 (47.9-58.8) 58.6 (50.9-68.4)*3 51.1 (47.7-56.8)§2 
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REE (kcal/day) 1720 (1549-1920) 1809 (1631-2057)* 1711 (1570-1904) 
REEFFM 31.5 (28.6-34.4) 30.5 (27.7-33.3)* 32 (30.2-35.5)§ 
L-T4 dose (µg/day) 100 (75-125) 100 (50-136) 125 (92-150) *1, § 
L-T4 dose BW (µg/kg/day) 0.90 (0.62-1.14) 0.84 (0.49-1.14)* 1.16 (0.94-1.37)*2, §3 
TSH (mU/liter) 1.80 (1.02-2.80) 5.90 (4.92-8.12)*3 0.07 (0.03-0.15)*3, §3 
fT4 (ng/liter) 12.1 (11.0-13.6) 11.1 (9.9-12.4)*3 14.3 (12.7-16.0)*3, §3 
Glucose (mg/dL) 96 (88-113) 101 (90-119) 95 (88-107) 
Insulin (mU/liter) 12.7 (8.9-17.7) 14.3 (8.8-21.8)* 13.8 (9.6-18.3) 
HOMA-IR 3.0 (2.1-4.6) 3.6 (2.1-6.0)* 3.2 (2.2-5.0) 
CHO (mg/dL) 192 (168-218) 189 (166-226) 181 (155-213) 
LDL-CHO (mg/dL) 120 (99-143) 121 (95-147) 104 (89-140) 
HDL-CHO (mg/dL) 47 (38-57) 46 (40-55) 47 (41-53) 
TG (mg/dL) 127 (102-174) 141 (100-183) 126 (85-153) 
CRP (mg/dL) 0.65 (0.38-1.17) 0.64  (0.39-1.23) 0.82 (0.50-1.05) 
For abbreviations: BMI, body mass index; WHR, Waist-to-hip ratio, FM, fat mass; FFM, fat-free mass; REE, 
resting energy expenditure; TSH, thyroid-stimulating hormone; fT4, free thyroxine; HOMA-IR, homeostatic 
model of insulin resistance; CHO, total cholesterol; LDL, low density lipoprotein; HDL, high density 
lipoprotein; TG, triglycerides. 
Table 3. Summary of anthropometric and thyroid function data obtained in obese L-T4 
users divided according to age <65 and ≥65 years. Data are expressed as median, with 
interquartile range in parentheses, or percentage. Comparison between populations was 
performed by ANOVA and χ2 test. 
Variables Patients aged <65 yr (n = 453) Patients aged ≥65 yr (n = 238) p 
Males/Females (N, %) 55/397 (12.1/87.9) 31/207 (13/87) 0.7 
Age (years) 54 (45-58) 71 (69-74) <0.0001 
BMI (kg/m2) 44.3 (40.3-49.4) 43.2 (39.7-47.2) <0.01 
FM (%) 50.1 (45.9-53.5) 52.4 (48.0-55.4) <0.0001 
FFM (kg) 55.3 (50.7-61.6) 49.5 (45.5-56.5) <0.0001 
L-T4 dose (µg/day) 100 (75-132) 100 (50-125) <0.0001 
L-T4 dose (µg/kg/day) 0.93 (0.66-1.18) 0.88 (0.55-1.14) <0.05 
TSH (mU/liter) 1.99 (0.88-3.83) 2.14 (1.10-3.26) 0.3 
fT4 (ng/liter) 11.9 (10.8-13.6) 12.3 (10.9-13.7) 0.5 
CRP (mg/dL) 0.7 (0.4-1.3) 0.5 (0.3-1) <0.001 
Adequately treated (%) 319 (70.6%) 200 (84.0%) <0.05 
Under-treated (%) 92 (20.4%) 38 (16.0%) 0.2 
Over-treated (%) 41 (9.1%) 11 (4.6%) <0.05 
For abbreviations: BMI, body mass index; TSH, thyroid-stimulating hormone; fT4, free thyroxine; BW, body 
weight. 
Table 4. Bivariate correlation analysis between the daily L-T4 and L-T4 µg/kg dose and 
anthropometric or metabolic variables in L-T4 users. Significant correlations are shown in 
bold character and expressed as ρ values. For significance: *, p <0.05, *1, p<0.01, *2, 
p<0.001, *3, p<0.0001. 
Variables L-T4/day L-T4 µg/kg/day 
Gender 0.04 -0.05 
Age (years) -0.15*3 -0.05 
BMI (kg/m2) 0.09* -0.19*3 
WC (cm) 0.11* 0.16*3 
FM (%) -0.003 -0.12*1 
FFM (kg) 0.19*3 -0.11*1 
REE (kcal/day) 0.14*1 -0.11* 
REEFFM 0.02 0.04 
TSH (mU/liter) -0.13*3 -0.20*3 
fT4 (ng/liter) 0.24*3 0.28*3 
Glucose (mg/dL) 0.02 0.01 
Insulin (mU/liter) -0.02 -0.07 
HOMA-IR -0.01 -0.05 
CHO (mg/dL) -0.04 -0.03 
LDL-CHO (mg/dL) -0.01 -0.01 
HDL-CHO (mg/dL) -0.06 -0.02 
TG (mg/dL) -0.01 -0.01 
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For abbreviations: BMI, body mass index; WC, Waist Circumference, FM, fat mass; FFM, fat-free mass; REE, 
resting energy expenditure; TSH, thyroid-stimulating hormone; fT4, free thyroxine; HOMA-IR, homeostatic 
model of insulin resistance; CHO, total cholesterol; LDL, low density lipoprotein; HDL, high density 
lipoprotein; TG, triglycerides. 
Table 5. Odds ratios (ORs) for L-T4 over-treatment and under-treatment vs. adequate 
treatment. Significant correlations are shown in bold character. 
Covariates L-T4 over-treatment L-T4 under-treatment 
 OR (95% CI) p-value OR (95% CI) p-value 
Age 0.96 (0.94-0.99) 0.001 0.99 (0.97-1.01) 0.2 
Gender     
Female 1 Ref. 1 Ref. 
Male 1.75 (0.55-5.59) 0.3 2.37 (1.10-5.11) 0.03 
BMI 0.93 (0.88-0.99) 0.01 1.01 (0.98-1.05) 0.5 
L-T4 dose (µg/kg/day) 2.98 (1.44-6.14) 0.003 1.02 (0.59-1.78) 0.9 
Duration of hypothyroidism 0.99 (0.95-1.04) 0.8 0.99 (0.96-1.02) 0.5 
FFM (kg) 0.98 (0.95-1.02) 0.3 1.01 (0.99-1.04) 0.3 
Cause of hypothyroidism     
AITD (0) 1 Ref. 1 Ref. 
Thyroidectomy 
(1) 
1.38 (0.58-3.25) 0.5 0.56 (0.29-1.27) 0.2 
Presence of diabetes mellitus     
No (0) 1 Ref. 1 Ref. 
Yes (1) 1.30 (0.45-3.22) 0.7 0.47 (0.40-1.55) 0.5 
For abbreviations: BMI, body mass index; FFM, free fat mass; AITD, autoimmune thyroid disease 
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